Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prime Medicine (PRME) EBITDA (2021 - 2025)

Prime Medicine (PRME) has disclosed EBITDA for 5 consecutive years, with -$46.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 8.83% year-over-year to -$46.0 million, compared with a TTM value of -$201.1 million through Dec 2025, down 2.65%, and an annual FY2025 reading of -$201.1 million, down 2.65% over the prior year.
  • EBITDA was -$46.0 million for Q4 2025 at Prime Medicine, up from -$50.5 million in the prior quarter.
  • Across five years, EBITDA topped out at -$16.4 million in Q3 2021 and bottomed at -$65.5 million in Q4 2023.
  • Average EBITDA over 5 years is -$44.2 million, with a median of -$45.9 million recorded in 2024.
  • Peak annual rise in EBITDA hit 36.27% in 2022, while the deepest fall reached 80.96% in 2022.
  • Year by year, EBITDA stood at -$61.5 million in 2021, then soared by 36.27% to -$39.2 million in 2022, then crashed by 67.06% to -$65.5 million in 2023, then soared by 35.43% to -$42.3 million in 2024, then fell by 8.83% to -$46.0 million in 2025.
  • Business Quant data shows EBITDA for PRME at -$46.0 million in Q4 2025, -$50.5 million in Q3 2025, and -$52.6 million in Q2 2025.